Logotype for Kodiak Sciences Inc

Kodiak Sciences (KOD) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Kodiak Sciences Inc

Q3 2026 earnings summary

12 Nov, 2026

Executive summary

  • Three late-stage retinal programs advanced; no product revenue to date and operating losses continue.

  • Zenkuda and KSI-501 met DAYBREAK one-year visual-acuity endpoints; a three-indication Zenkuda BLA is planned for Q4 2026.

  • KSI-101 PEAK first-cohort topline results remain on track for December 2026; substantial doubt exists about going-concern status.

Financial highlights

  • Q3 2026 R&D expense was $58.3M vs. $50.5M YoY; G&A was $8.8M vs. $11.9M, reflecting a non-cash lease-termination gain.

  • Q3 net loss was $66.2M, or $1.05/share, vs. $61.5M, or $1.16/share; nine-month net loss was $190.0M vs. $173.2M.

  • Nine-month operating expenses rose to $193.7M from $176.9M; net cash used in operations was $130.1M vs. $96.6M.

  • Cash and cash equivalents were $88.7M at September 30, 2026, down from $209.9M at December 31, 2025; cash, cash equivalents and restricted cash totaled $92.6M.

  • Accumulated deficit was $1.75B and stockholders’ equity was $12.6M at September 30, 2026.

Outlook and guidance

  • Zenkuda three-indication BLA for wet AMD, diabetic retinopathy and retinal vein occlusion planned for Q4 2026.

  • KSI-101 PEAK first-cohort topline results expected in December 2026; second-cohort enrollment across PEAK and PINNACLE expected to finish in Q4 2026, with data anticipated in Q2 2027.

  • KSI-101 BLA filing planned for Q2 2027, conditional on successful PEAK and PINNACLE results.

  • Cash may not cover operating and capital needs for the 12 months following the report; additional financing is planned, though cash was expected to support current and planned operations into 2027.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Kodiak Sciences